Objectives: Research indicates that active smokers are at risk of cognitive impairment. However, the correlation between chronic passive smoking and the risk of cognitive impairment remains underexplored. This study aimed to determine the association between smoking, passive smoking, and cognitive impairment and examined the dose-response effect.
Methods: This population-based two-year survey was conducted in four rural public health centers from 2021 to 2023 in Central Java, Indonesia, each center caters to approximately 30 000 people. The participants were selected using simple random sampling from the health center visitors aged 30-60 years. Smoking and passive smoking were determined by self-assessment. Mini-Mental State Examination was used to evaluate cognitive impairment. The potential impact of confounding variables such as lifestyle, sociodemographic factors, and chronic diseases were considered and excluded during statistical analysis.
Results: The participants were 409 individuals aged 30-60 years. The majority were men (264; 64.5%). Among them, 308 (75.3%) were active smokers, 271 (66.3%) were passive smokers, and 138 (33.7%) were not exposed to tobacco smoke. There was a significant relationship between cognitive impairment and increasing pack years of active smoking. The highest and most significant risk was observed in those who smoked ≥ 20 pack-years with an adjusted odds ratio (aOR) of 1.61 and 95% CI: 0.98-2.31. Passive smokers had a slightly lower risk of cognitive impairment than those who did not smoke and never smoked (aOR = 2.01; 95% CI: 1.37-2.70). They were comparable with OR of 10-19 pack-years total exposure to active smoking (aOR = 1.86; 95% CI: 1.24-2.42).
Conclusions: There was a dose-response relationship between smoking and cognitive impairment with a significant effect on ≥ 20 pack-years of exposure. Passive smoking also indicated a significant risk of cognitive impairment equivalent to an estimated 10-19 pack-years of active smoking.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711741 | PMC |
| http://dx.doi.org/10.5001/omj.2024.94 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The P200 ERP Response in Mild Cognitive Impairment and the Aging Population.
Clin EEG Neurosci
January 2025
Palma Sola Neurology Associates, Bradenton, FL, USA.
Evoked potential metrics extracted from an EEG exam can provide novel sources of information regarding brain function. While the P300 occurring around 300 ms post-stimulus has been extensively investigated in relation to mild cognitive impairment (MCI), with decreased amplitude and increased latency, the P200 response has not, particularly in an oddball-stimulus paradigm. This study compares the auditory P200 amplitudes between MCI (28 patients aged 74(8)) and non-MCI, (35 aged 72(4)).
View Article and Find Full Text PDFDifferences of longitudinal plasma biomarkers between single memory domain and multidomain subject cognitive decline: Evidence from SILCODE.
J Alzheimers Dis
January 2025
Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
Background: Plasma biomarkers demonstrated potential in identifying amyloid pathology in early Alzheimer's disease. Different subtypes of subjective cognitive decline (SCD) may lead to different cognitive impairment conversion risks.
Objective: To investigate the differences of plasma biomarkers in SCD subtypes individuals, which were unclear.
Urinary formic acid is associated with cerebral amyloid deposition and glucose metabolism in memory clinic patients.
J Alzheimers Dis
January 2025
Department of Gerontology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: Urinary formic acid (FA) has been reported to be a biomarker for Alzheimer's disease (AD). However, the association between FA and pathological changes in memory clinic patients is currently unclear.
Objective: This study aims to investigate associations between FA and pathological changes across different cognitive statuses in memory clinic patients.
Predicting cognitive decline from neuropsychiatric symptoms and Alzheimer's disease biomarkers: A machine learning approach to a population-based data.
J Alzheimers Dis
January 2025
Department of Neurology and the Franke Barrow Global Neuroscience Education Center, Barrow Neurological Institute, Phoenix, AZ, USA.
Background: The aim of this study was to examine the potential added value of including neuropsychiatric symptoms (NPS) in machine learning (ML) models, along with demographic features and Alzheimer's disease (AD) biomarkers, to predict decline or non-decline in global and domain-specific cognitive scores among community-dwelling older adults.
Objective: To evaluate the impact of adding NPS to AD biomarkers on ML model accuracy in predicting cognitive decline among older adults.
Methods: The study was conducted in the setting of the Mayo Clinic Study of Aging, including participants aged ≥ 50 years with information on demographics (i.
The canine blood-brain barrier in health and disease: focus on brain protection.
Vet Q
December 2025
Department of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
This review examines the role of the canine blood-brain barrier (BBB) in health and disease, focusing on the impact of the multidrug resistance (MDR) transporter P-glycoprotein (P-gp) encoded by the gene. The BBB is critical in maintaining central nervous system homeostasis and brain protection against xenobiotics and environmental drugs that may be circulating in the blood stream. We revise key anatomical, histological and functional aspects of the canine BBB and examine the role of the gene mutation in specific dog breeds that exhibit reduced P-gp activity and disrupted drug brain pharmacokinetics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!